What is Vyleesi
Vyleesi (bremelanotide) is an FDA-approved, self-administered subcutaneous injection specifically indicated for treating acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women—characterized by low sexual desire causing marked distress or interpersonal difficulty that is NOT due to medical/psychiatric conditions, relationship problems, or medication effects. 1
Mechanism and Pharmacology
Vyleesi is a melanocortin receptor agonist, specifically a synthetic peptide analogue of alpha melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor, which modulates brain pathways involved in sexual response 2. This central nervous system mechanism distinguishes it from hormonal approaches.
Dosing and Administration
The recommended dose is 1.75 mg administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity 1. Critical dosing parameters include:
- Maximum frequency: One dose per 24 hours
- Monthly limit: No more than 8 doses per month recommended
- Trial period: Discontinue after 8 weeks if no symptom improvement 1
The duration of efficacy after each dose remains incompletely characterized, so patients should determine optimal timing based on their individual response to desire enhancement and tolerability of adverse effects 1.
Efficacy Evidence
The two pivotal Phase 3 RECONNECT trials (studies 301 and 302) demonstrated statistically significant improvements in both coprimary endpoints compared to placebo 3:
- Sexual desire improvement (Female Sexual Function Index-desire domain): Integrated studies showed 0.35-point increase (P<.001)
- Distress reduction (Female Sexual Distress Scale item 13): Integrated studies showed -0.33-point reduction (P<.001)
Long-term data from the 52-week open-label extension showed sustained improvements, with desire domain scores increasing 1.25-1.30 points and distress scores decreasing -1.4 to -1.7 points from baseline in patients continuing bremelanotide 4. A recent 2026 meta-analysis confirmed that bremelanotide improves both desire and arousal subscales as well as total FSFI scores 5.
Safety Profile and Adverse Events
The most common adverse events from the integrated Phase 3 studies were 6:
- Nausea: 40.0% (vs. 1.3% placebo) - most common reason for discontinuation
- Flushing: 20.3% (vs. 1.3% placebo)
- Headache: 11.3% (vs. 1.9% placebo)
- Injection site reactions: 5.4% (vs. 0.5% placebo)
Most adverse events were mild to moderate in intensity. Across the entire clinical development program involving 3,500 subjects in 43 studies, there were no deaths and few serious adverse events 6.
Critical Warnings and Contraindications
Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease 1. This stems from predictable hemodynamic effects:
- Blood pressure increases: Maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2-4 hours post-dose
- Heart rate reduction: Up to 5 beats per minute decrease
- Duration: Effects typically resolve within 12 hours 1
Focal hyperpigmentation is a specific risk, particularly with frequent dosing. While rare when following label recommendations (≤8 doses/month), it occurred in over one-third of subjects receiving 16 consecutive daily doses 6. This underscores the importance of adhering to monthly dosing limits.
Clinical Context and Limitations
Vyleesi is NOT indicated for:
- Postmenopausal women
- Men
- Enhancing sexual performance 1
Important clinical caveat: Flibanserin and bremelanotide have not been evaluated in women with cancer history or those on endocrine therapy 7. The ASCO guidelines note uncertainty regarding the risk/benefit ratio in these populations 7.
Place in Therapy
Vyleesi represents one of only two FDA-approved pharmacological options for HSDD in premenopausal women (the other being flibanserin, a daily oral medication). Recent evidence suggests combining medical and psychological approaches may be optimal 8, though the 2026 meta-analysis found that bremelanotide specifically improves desire, arousal, and reduces distress as monotherapy 5.
Key clinical advantage: On-demand dosing allows patients to use medication only when desired, unlike daily flibanserin. However, the clinical benefit, while statistically significant, may be modest 9, and patient selection should involve shared decision-making about expectations and tolerability, particularly regarding nausea.